Celularity (CELU) Competitors $2.15 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.17 +0.02 (+0.74%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CELU vs. LYEL, FENC, ACIU, EDIT, IMMP, TKNO, HUMA, VYGR, HRTX, and PRQRShould you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Lyell Immunopharma (LYEL), Adherex Technologies (FENC), AC Immune (ACIU), Editas Medicine (EDIT), Prima BioMed (IMMP), Alpha Teknova (TKNO), Humacyte (HUMA), Voyager Therapeutics (VYGR), Heron Therapeutics (HRTX), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Celularity vs. Its Competitors Lyell Immunopharma Adherex Technologies AC Immune Editas Medicine Prima BioMed Alpha Teknova Humacyte Voyager Therapeutics Heron Therapeutics ProQR Therapeutics Lyell Immunopharma (NASDAQ:LYEL) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership. Do insiders and institutionals have more ownership in LYEL or CELU? 66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Comparatively, 22.1% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, LYEL or CELU? Lyell Immunopharma has a beta of -0.19, suggesting that its stock price is 119% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Does the media refer more to LYEL or CELU? In the previous week, Lyell Immunopharma and Lyell Immunopharma both had 1 articles in the media. Lyell Immunopharma's average media sentiment score of 1.21 beat Celularity's score of 0.88 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate LYEL or CELU? Lyell Immunopharma presently has a consensus price target of $15.00, suggesting a potential upside of 21.85%. Celularity has a consensus price target of $6.00, suggesting a potential upside of 179.07%. Given Celularity's stronger consensus rating and higher probable upside, analysts clearly believe Celularity is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Celularity 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is LYEL or CELU more profitable? Celularity has a net margin of -165.22% compared to Lyell Immunopharma's net margin of -552,328.31%. Lyell Immunopharma's return on equity of -85.58% beat Celularity's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-552,328.31% -85.58% -68.85% Celularity -165.22%-459.57%-57.71% Which has higher earnings and valuation, LYEL or CELU? Celularity has higher revenue and earnings than Lyell Immunopharma. Celularity is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$60K3,941.25-$342.99M-$24.29-0.51Celularity$54.22M1.06-$57.89M-$3.18-0.68 SummaryCelularity beats Lyell Immunopharma on 9 of the 15 factors compared between the two stocks. Get Celularity News Delivered to You Automatically Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CELU vs. The Competition Export to ExcelMetricCelularityMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.39M$3.12B$5.75B$10.31BDividend YieldN/A2.37%5.89%4.63%P/E Ratio-0.6821.0376.6626.52Price / Sales1.06251.18445.6888.95Price / CashN/A45.4837.2260.63Price / Book5.819.5613.946.31Net Income-$57.89M-$53.02M$3.29B$271.37M7 Day Performance-8.51%0.37%0.63%2.11%1 Month Performance-38.22%3.93%4.32%6.67%1 Year Performance-22.38%8.61%84.13%27.84% Celularity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CELUCelularity1.5615 of 5 stars$2.15flat$6.00+179.1%-22.9%$57.39M$54.22M-0.68220High Trading VolumeLYELLyell Immunopharma2.9759 of 5 stars$13.13+2.4%$15.00+14.2%-46.7%$246.29M$60K-0.54270Positive NewsGap DownFENCAdherex Technologies2.4923 of 5 stars$8.67-1.0%$13.33+53.8%+70.2%$244.50M$47.54M-20.6410ACIUAC Immune2.6331 of 5 stars$2.48+2.1%$10.00+303.2%-22.3%$244M$31.02M-4.28140Positive NewsEDITEditas Medicine4.1536 of 5 stars$2.67-0.7%$5.10+91.0%-26.1%$241.88M$32.31M-0.94230IMMPPrima BioMed1.4848 of 5 stars$1.73+5.5%$7.00+304.6%-26.8%$240.73M$6.69M0.002,021TKNOAlpha Teknova2.8195 of 5 stars$4.53+1.8%$10.00+120.8%+2.7%$238.14M$37.74M-10.79240Positive NewsHUMAHumacyte2.8152 of 5 stars$1.53+4.1%$9.75+537.3%-70.3%$232.81M$1.57M-3.40150Analyst ForecastVYGRVoyager Therapeutics3.8394 of 5 stars$4.21+0.7%$13.25+214.7%-31.8%$231.86M$42.58M-2.28100News CoveragePositive NewsAnalyst ForecastGap UpHRTXHeron Therapeutics4.1038 of 5 stars$1.24-1.6%$4.50+262.9%-32.2%$230.98M$144.29M-62.00300Positive NewsPRQRProQR Therapeutics2.6324 of 5 stars$1.99-9.1%$8.00+302.0%+8.7%$230.42M$16.49M-4.33180News CoveragePositive NewsShort Interest ↑ Related Companies and Tools Related Companies LYEL Competitors FENC Competitors ACIU Competitors EDIT Competitors IMMP Competitors TKNO Competitors HUMA Competitors VYGR Competitors HRTX Competitors PRQR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CELU) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celularity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celularity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
